Patent Issued for Chimeric bacteriophage lysin with activity against Staphylococci bacteria (USPTO 11827911).

A patent has been issued for a new type of bacteriophage lysin called ClyS, which has been developed to target Staphylococcus aureus bacteria. S. aureus is a pathogen that causes various infections in humans and the emergence of drug-resistant strains, such as MRSA, is a major concern. Bacteriophage lysins are antimicrobial agents that can degrade the cell wall of susceptible bacteria and cause cell lysis. ClyS is unique because it combines the catalytic domain of one lysin with a binding domain from another, and it does not contain a domain that may lead to resistance. ClyS may have potential for both treatment and diagnostic purposes. [Extracted from the article]